title: Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
abstract: OBJECTIVE
  To increase the safety and effectiveness of treatments for overactive bladder (OAB) with moderate symptoms in elderly patients.
  
  
  METHODS
  Patients were examined at the Urodynamic Department of the Regional Diagnostic Center (Vladivostok, Russian Federation) from September 1, 2012 to December 31, 2012. The assignment of patients [n = 177, average age 69. 4 years, 98 women (55.4%) and 79 men (44.6%)] was random and blind in this placebo-controlled study. Patients were distributed into subgroups according to the method of treatment as follows: group А1: n = 57, trospium 30 mg/day + solifenacin 10 mg/day; group А2: n = 61, trospium 15 mg/day + solifenacin 5 mg/day; group А3: n = 59, placebo. All patients underwent a urodynamic examination in accordance with international standards before and 2 months after treatment. ICIQ-SF questionnaires recommended by the International Continence Society (ICS) and bladder diaries were used to evaluate the clinical results. The clinical severity of the OAB symptoms and the effectiveness of the treatment were evaluated based on the frequency of episodes of incontinence (EI) per day. Three or fewer EI per day were considered moderate dysfunction of the lower urinary tract.
  
  
  RESULTS
  Groups of elderly patients with moderate symptoms of OAB who were treated with standard- and low-dose trospium and solifenacin demonstrated a significant increase in the median values of reflex volume, bladder capacity, and detrusor compliance and a decrease in the frequency of urination and urinary urgencies. The frequency of EI in both of the main groups decreased by almost 2-fold in comparison to the initial data and reached the following values: group А1: 1.27 (-1.08), p ≤ 0.05; group A2: 1.49 (-1.18), p ≤ 0.05. The correlation with the decrease in the frequency of EI in these groups was r = 0.85 (p ≤ 0.01). The percentage of patients with a significant decrease (EI ≥1.0) among those treated with standard- and low-dose trospium and solifenacin increased synchronously, prompting us to suppose the absence of a direct correlation between medicine dose and therapeutic effect for moderate OAB symptoms.
  
  
  CONCLUSIONS
  The combination of low-dose trospium and solifenacin provides good clinical and urodynamic effects in elderly patients with moderate symptoms of OAB. Combination of these drugs in standard doses for such patients is excessive.
authors.affiliation: Department of Adaptive Medicine, Institute of Physical Health, Far Eastern Federal University, Vladivostok, Russian Federation.
authors.forename: Kirill V
authors.initials: KV
authors.lastname: Kosilov
authors.forename: Sergey A
authors.initials: SA
authors.lastname: Loparev
authors.forename: Marina A
authors.initials: MA
authors.lastname: Ivanovskaya
authors.forename: Liliya V
authors.initials: LV
authors.lastname: Kosilova
mesh_terms: D000367:Age Factors; D000368:Aged; D001561:Benzilates / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D009662:Nortropanes / Q000008:administration & dosage* / Q000009:adverse effects; D011812:Quinuclidines / Q000008:administration & dosage* / Q000009:adverse effects; D012426:Russia; D012720:Severity of Illness Index; D012737:Sex Factors; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects; D064804:Urological Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D001561:Benzilates; D018727:Muscarinic Antagonists; D009662:Nortropanes; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D064804:Urological Agents; C003330:trospium chloride; D000069464:Solifenacin Succinate